Study S003261

Pharmacokinetics of RAY1225 Following Administration to Subjects With Impaired Renal Function

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06613763
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 32
Start: 2024-09-11
Primary completion: 2025-01-10
Lead sponsor: Guangdong Raynovent Biotech Co., Ltd
Conditions: Kidney Impairment
Interventions: DRUG:RAY1225
Results posted: FALSE

Registered primary outcomes

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of RAY1225 From Time Zero to T (AUC[0-t]) [Baseline through Day 43]
PK: Maximum Concentration of RAY1225 [Baseline through Day 43]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.